インサイダー取引

EDGAR

Evoke Pharma Inc

取締役、役員、10%超の株主がSECのForm 3、4、5で報告した取引を、各提出書類のXMLから読み取っています。コードとその文言はSEC自身のものです。

Form 4は取引から2営業日以内に提出する必要があるため、直近の取引はまだ提出されていない場合があります。

期間:2025年11月16日以降の日付の取引。

市場での購入(コードP)
0件の取引、—株
市場での売却(コードS)
0件の取引、—株

合計は掲載した提出済み取引を足したもので、報告された内容の集計であり、方向性を示すものではありません。

37件中1–37件を表示

SECのForm 3、4、5で提出されたインサイダー取引(新しい順)
日付報告者コード取得または処分株数1株あたり価格(提出どおり)価値(算出)取引後の保有株数直接または間接ルール10b5-1のチェック欄注記出典
2025年12月17日 2025年12月19日に提出Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
処分(D)148,15311.00
1,629,683

算出:株数 × 1株あたり価格。正確な値 1629683.00。

0間接(I) See Footnoteいいえ
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
提出書類を開く 0001104659-25-123156 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月19日に提出Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

デリバティブ証券: Prefunded Warrants — 原資産 Common Stock (433,962) — 行使価格 0.0001
処分(D)433,96210.999
4,773,148.038

算出:株数 × 1株あたり価格。正確な値 4773148.038。

0間接(I) See Footnoteいいえ
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
提出書類を開く 0001104659-25-123156 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月19日に提出Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

デリバティブ証券: Series A Common Stock Purchase Warrants — 原資産 Common Stock (117,019) — 行使価格 8.16
処分(D)117,0194.71
551,159.49

算出:株数 × 1株あたり価格。正確な値 551159.49。

0間接(I) See Footnoteいいえ
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
提出書類を開く 0001104659-25-123156 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月19日に提出Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

デリバティブ証券: Series C Common Stock Purchase Warrants — 原資産 Common Stock (117,019) — 行使価格 8.16
処分(D)117,0194.71
551,159.49

算出:株数 × 1株あたり価格。正確な値 551159.49。

0間接(I) See Footnoteいいえ
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
提出書類を開く 0001104659-25-123156 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月19日に提出Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

デリバティブ証券: Amended Series A Common Stock Purchase Warrants — 原資産 Common Stock (158,531) — 行使価格 0.01
処分(D)158,53110.99
1,742,255.69

算出:株数 × 1株あたり価格。正確な値 1742255.69。

0間接(I) See Footnoteいいえ
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
提出書類を開く 0001104659-25-123156 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月19日に提出Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

デリバティブ証券: Amended Series C Common Stock Purchase Warrants — 原資産 Common Stock (250,627) — 行使価格 0.01
処分(D)250,62710.99
2,754,390.73

算出:株数 × 1株あたり価格。正確な値 2754390.73。

0間接(I) See Footnoteいいえ
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
提出書類を開く 0001104659-25-123156 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,218) — 行使価格 5.41
処分(D)1,218——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322642 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,833) — 行使価格 4.45
処分(D)5,833——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322642 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,218) — 行使価格 3.453
処分(D)1,218——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322642 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,479) — 行使価格 5.41
処分(D)1,479——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322643 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (8,750) — 行使価格 4.45
処分(D)8,750——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322643 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,291) — 行使価格 3.453
処分(D)1,291——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322643 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,187) — 行使価格 5.41
処分(D)1,187——0直接(D) いいえ
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322641 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,833) — 行使価格 4.45
処分(D)5,833——0直接(D) いいえ
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322641 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,187) — 行使価格 3.453
処分(D)1,187——0直接(D) いいえ
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322641 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,250) — 行使価格 5.41
処分(D)1,250——0直接(D) いいえ
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322638 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,833) — 行使価格 4.45
処分(D)5,833——0直接(D) いいえ
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322638 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,250) — 行使価格 3.453
処分(D)1,250——0直接(D) いいえ
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322638 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,218) — 行使価格 5.41
処分(D)1,218——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322639 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,833) — 行使価格 4.45
処分(D)5,833——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322639 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,187) — 行使価格 3.453
処分(D)1,187——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322639 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,833) — 行使価格 5.51
処分(D)5,833——0直接(D) いいえ
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322645 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,125) — 行使価格 3.453
処分(D)1,125——0直接(D) いいえ
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322645 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (17,291) — 行使価格 5.27
処分(D)17,291——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322644 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (11,000) — 行使価格 4.45
処分(D)11,000——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322644 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (64,840) — 行使価格 5.27
処分(D)64,840——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322637 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (70,000) — 行使価格 4.45
処分(D)70,000——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322637 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (17,291) — 行使価格 5.27
処分(D)17,291——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322640 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (13,000) — 行使価格 4.45
処分(D)13,000——0直接(D) いいえ
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322640 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (5,833) — 行使価格 5.26
処分(D)5,833——0直接(D) いいえ
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322646 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月17日 2025年12月17日に提出PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (1,155) — 行使価格 3.453
処分(D)1,155——0直接(D) いいえ
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
提出書類を開く 0001193125-25-322646 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月16日 2025年12月17日に提出Hill Malcolm R Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
処分(D)133——0直接(D) いいえ
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
提出書類を開く 0001193125-25-322642 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月16日 2025年12月17日に提出GARNER CAM L Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
処分(D)2,330——0間接(I) By Garner Investments, L.L.C.いいえ
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
提出書類を開く 0001193125-25-322643 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月16日 2025年12月17日に提出Brady Todd C Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
処分(D)27——0直接(D) いいえ
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
提出書類を開く 0001193125-25-322639 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月16日 2025年12月17日に提出CARLSON MARILYN R. Officer: Chief Medical Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
処分(D)360——0直接(D) いいえ
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
提出書類を開く 0001193125-25-322644 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月16日 2025年12月17日に提出D'Onofrio Matthew J Director · Officer: Chief Executive Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
処分(D)15,509——0直接(D) いいえ
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
提出書類を開く 0001193125-25-322637 提出書類のXMLから読み取り この行に異議を申し立てる
2025年12月16日 2025年12月17日に提出Kowieski Mark Officer: Chief Financial Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
処分(D)11,815——0直接(D) いいえ
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
提出書類を開く 0001193125-25-322640 提出書類のXMLから読み取り この行に異議を申し立てる

機関投資家の保有(Form 13F)

この発行体に結び付いたForm 13Fの保有はストアにありません。未リンクまたは未提出の保有者はゼロではなく、不在です。

5%保有者(Schedule 13D・13G)

SECの構造化形式(2024年末以降)で提出されたスケジュールをここで読み取ります。それ以前のものは自由形式のテキストで、読み取っていません。

5%保有者(新しい事由順、提出どおり)
保有者クラスに占める割合保有株数事由日書式出典
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share00.0012/17/2025 2025年12月19日に提出SCHEDULE 13D/A訂正 5提出書類を開く 0001104659-25-123157 この行に異議を申し立てる
Harkey Wilmot B. Common Stock, par value $0.0001 per share00.0012/17/2025 2025年12月19日に提出SCHEDULE 13D/A訂正 5提出書類を開く 0001104659-25-123157 この行に異議を申し立てる
Mack Daniel Common Stock, par value $0.0001 per share00.0012/17/2025 2025年12月19日に提出SCHEDULE 13D/A訂正 5提出書類を開く 0001104659-25-123157 この行に異議を申し立てる
Morgan Stanley Common Stock0.03111/30/2025 2025年12月5日に提出SCHEDULE 13G/A訂正 1提出書類を開く 0000895421-25-000595 この行に異議を申し立てる
Morgan Stanley Smith Barney LLC Common Stock0.03111/30/2025 2025年12月5日に提出SCHEDULE 13G/A訂正 1提出書類を開く 0000895421-25-000595 この行に異議を申し立てる
Klein Roger M. Common Stock, par value $0.0001 per share10.5163,000.0011/04/2025 2025年11月12日に提出SCHEDULE 13D提出書類を開く 0001651175-25-000007 この行に異議を申し立てる
Krieger Charitable Trust Common Stock, par value $0.0001 per share8.3129,000.0011/04/2025 2025年11月12日に提出SCHEDULE 13D提出書類を開く 0001651175-25-000007 この行に異議を申し立てる
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 2025年11月4日に提出SCHEDULE 13D/A訂正 4提出書類を開く 0001104659-25-106048 この行に異議を申し立てる
Harkey Wilmot B. Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 2025年11月4日に提出SCHEDULE 13D/A訂正 4提出書類を開く 0001104659-25-106048 この行に異議を申し立てる
Mack Daniel Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 2025年11月4日に提出SCHEDULE 13D/A訂正 4提出書類を開く 0001104659-25-106048 この行に異議を申し立てる
Morgan Stanley Common Stock10.5163,71808/31/2025 2025年9月8日に提出SCHEDULE 13G提出書類を開く 0000895421-25-000528 この行に異議を申し立てる
Morgan Stanley Smith Barney LLC Common Stock10.5163,71808/31/2025 2025年9月8日に提出SCHEDULE 13G提出書類を開く 0000895421-25-000528 この行に異議を申し立てる

割合は提出書類が指定するクラスに対するもので、保有者の申告どおりです。グループの構成員はそれぞれグループの株式を報告するため、行を合算しないでください。

読み込んだ内容

2004年6月14日から2026年11月13日までの提出書類2,092,408件を読み込み:Form 3, 3/A, 4, 4/A, 5, 5/A。

アーカイブの読み込み中は、不完全な年があります。ここで提出数が少ない年が、実際に少なかったという意味ではありません。

提出年別の読み込み件数
提出年読み込み件数
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024185,386
2025235,520
2026254,737

SECがXMLを義務付ける前の提出書類は一覧にあるだけで、内容は抽出していません。

Evoke Pharma Incに戻る